Senticell
Senticell is developing a liquid-biopsy diagnostic based on nucleic acids associated with red blood cells.
$7MSeed
ParticipantEC
Evoce Capital
Activity from announced rounds
Activity in this selectionUnited States
Evoce Capital is the investment firm named in Surf Therapeutics and Senticell financing histories.
Recorded funding activity
Surf develops non-invasive ultrasound neuromodulation for immune-mediated diseases. Senticell develops a liquid-biopsy diagnostic using nucleic acids associated with red blood cells. The companies pursue different therapeutic and diagnostic approaches rather than the same product.
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 1 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $13M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionSurf Therapeutics
Develops non-invasive ultrasound neuromodulation therapies to treat immune-mediated diseases
$6MSeed
Role not disclosed